Is the case really a SMARCA4-deficient thoracic sarcoma?

Affiliations

Comment

Kei Kunimasa. Thorac Cancer. 2021 Jan.

. 2021 Jan;12(1):140.

doi: 10.1111/1759-7714.13706. Epub 2020 Oct 19.

¹ Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.

No abstract available

Comment on

Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.
Takada K, Sugita S, Murase K, Kikuchi T, Oomori G, Ito R, Hayasaka N, Miyanishi K, Iyama S, Ikeda H, Kobune M, Emori M, Kato J, Hasegawa T. Takada K, et al. Thorac Cancer. 2019 Dec;10(12):2312-2315. doi: 10.1111/1759-7714.13215. Epub 2019 Oct 16. Thorac Cancer. 2019. PMID: 31617320 Free PMC article.
Response to 'Is the case really a SMARCA4-deficient thoracic sarcoma?'.
Takada K, Sugita S, Hasegawa T. Takada K, et al. Thorac Cancer. 2021 Jan;12(1):141. doi: 10.1111/1759-7714.13751. Epub 2020 Nov 18. Thorac Cancer. 2021. PMID: 33210422 Free PMC article. No abstract available.

1. Takada K, Sugita S, Murase K et al Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report. Thorac Cancer 2019; 10 (12): 2312–5. - PMC - PubMed
1. Rekhtman N, Montecalvo J, Chang JC et al SMARCA4‐deficient thoracic sarcomatoid tumors represent primarily smoking‐related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol 2020; 15 (2): 231–47. - PMC - PubMed
1. Yoshida A, Kobayashi E, Kubo T et al Clinicopathological and molecular characterization of SMARCA4‐deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol 2017; 30 (6): 797–809. - PubMed
1. Kunimasa K, Nakamura H, Sakai K, et al Patients with SMARCA4‐deficient thoracic sarcoma and severe skeletal‐related events. Lung Cancer. 2019; 132: 59–64. - PubMed